Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoarthritis (OA) of the Hip Clear all
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Of Tanezumab In Osteoarthritis

NCT00809783
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
226
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Not applicable Interventional

Gait After THA: Direct Anterior vs Manual Posterior vs Robotic Posterior

NCT07226973
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip
Interventions
Total hip arthroplasty via direct anterior approach (manual, non-robotic), Total hip arthroplasty via posterior approach (manual, non-robotic), Robotic-assisted total hip arthroplasty via posterior approach
Procedure
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 4 Interventional

Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

NCT06793982
View directory record Official record
Conditions
Hip Osteoarthritis
Interventions
Platelet Rich Plasma Joint Injection, Corticosteroid Injection
Device · Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
21 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)

NCT01920152
View directory record Official record
Conditions
Hip Osteoarthritis
Interventions
PRP, Hyaluronic Acid
Biological · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 72 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed Not applicable Interventional

Use of Cooled Radiofrequency for the Treatment of Hip Pain Associated With Hip OA Compared to Intra-articular Steroid Injections

NCT04329884
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Cooled RFA treatment with COOLIEF* device, intra-articular corticosteroid injection
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Platelet Rich Plasma for Musculoskeletal Conditions

NCT07231471
View directory record Official record
Conditions
Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Shoulder, Osteoarthritis Ankle, Elbow Osteoarthritis, Epicondylitis of the Elbow, Plantar Fasciitis of Both Feet, Tendinopathy
Interventions
Platelet Rich Plasma Injection, Platelet Rich Plasma Preparation
Biological · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

NCT03382262
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
El Cajon, California • La Mesa, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

NCT02336685
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Opioid
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

NCT04065074
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
FX006 32 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Tucson, Arizona • Canoga Park, California • La Mesa, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 24, 2026, 1:07 AM EDT
Active, not recruiting Not applicable Interventional

Conversations in Health Literacy Using AI Technology for Osteoarthritis Patients

NCT06778486
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis of the Hip or Knee
Interventions
Artificial Intelligence Chatbot
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

NCT07417891
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis, Mild Cognitive Impairment, MCI, Mild Cognitive Impairment (MCI), Dementia
Interventions
Well-formulated ketogenic diet
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
55 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Active, not recruiting Not applicable Interventional

TED Stocking vs. Reparel Garment After Hip Replacement

NCT07246200
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip
Interventions
Reparel Bioactive Sleeve, TED Stocking
Device
Lead sponsor
Reparel
Industry
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

NCT01141283
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Enrolling by invitation No phase listed Observational

MDR Vivacit-E Elevated Study

NCT07150221
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip, Avascular Necrosis of Bone of Hip, Protrusio Acetabuli, Traumatic Arthropathy-Hip, Slipped Capital Femoral Epiphyses, Fused Hip, Fracture of Pelvis, Diastrophic Variant
Interventions
Vivacit-E Elevated Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
South Bend, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Ultrasound and CT to Measure Muscle in Hip OA

NCT04061499
View directory record Official record
Conditions
Hip Osteoarthritis
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

NCT02301234
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Celecoxib 100 mg, Celecoxib 100 mg Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

NCT00325858
View directory record Official record
Conditions
Chronic Pain
Interventions
Tramadol HCl ER
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Jul 24, 2026, 1:07 AM EDT